ArticleNPJ breast cancer2024

The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer.

Kai C C Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.